Merck's lambrolizumab wins breakthrough status for melanoma

04/25/2013 | Fox Business

The FDA granted breakthrough therapy status to Merck's experimental antibody drug lambrolizumab as a treatment for advanced melanoma. Lambrolizumab, which targets the programmed death receptor, is also being evaluated as a treatment for nonsmall-cell lung cancer.

View Full Article in:

Fox Business

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY